

Emilie Le Rhun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6897111/publications.pdf>

Version: 2024-02-01

158
papers

9,970
citations

61857

43
h-index

42291

92
g-index

182
all docs

182
docs citations

182
times ranked

10195
citing authors

#	ARTICLE	IF	CITATIONS
1	EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nature Reviews Clinical Oncology, 2021, 18, 170-186.	12.5	826
2	European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncology, The, 2017, 18, e315-e329.	5.1	816
3	Lomustine and Bevacizumab in Progressive Glioblastoma. New England Journal of Medicine, 2017, 377, 1954-1963.	13.9	670
4	Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncology, The, 2013, 14, 64-71.	5.1	622
5	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro-Oncology, 2020, 22, 1073-1113.	0.6	543
6	Molecular targeted therapy of glioblastoma. Cancer Treatment Reviews, 2019, 80, 101896.	3.4	386
7	Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). Neuro-Oncology, 2017, 19, 162-174.	0.6	381
8	EANOâ€“ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. Annals of Oncology, 2017, 28, iv84-iv99.	0.6	331
9	Translation Initiator EIF4G1 Mutations in Familial Parkinson Disease. American Journal of Human Genetics, 2011, 89, 398-406.	2.6	250
10	Carcinomatous meningitis: Leptomeningeal metastases in solid tumors. , 2013, 4, 265.		245
11	EANO guideline on the diagnosis and management of meningiomas. Neuro-Oncology, 2021, 23, 1821-1834.	0.6	230
12	EANOâ€“ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. Annals of Oncology, 2021, 32, 1332-1347.	0.6	227
13	European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma. Lancet Oncology, The, 2017, 18, e330-e340.	5.1	195
14	The Evolving Landscape of Brain Metastasis. Trends in Cancer, 2018, 4, 176-196.	3.8	194
15	Leptomeningeal metastases: a RANO proposal for response criteria. Neuro-Oncology, 2017, 19, now183.	0.6	157
16	Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era. Cancer Treatment Reviews, 2017, 53, 128-137.	3.4	146
17	Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMOâ€“EONSâ€“EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. Annals of Oncology, 2020, 31, 1306-1319.	0.6	146
18	Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials. Neuro-Oncology, 2014, 16, 1176-1185.	0.6	141

#	ARTICLE	IF	CITATIONS
19	How did lomustine become standard of care in recurrent glioblastoma?. <i>Cancer Treatment Reviews</i> , 2020, 87, 102029.	3.4	119
20	Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications. <i>Neuro-Oncology</i> , 2019, 21, 571-584.	0.6	114
21	Natural history of primary progressive aphasia. <i>Neurology</i> , 2005, 65, 887-891.	1.5	108
22	Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 1700-1710.	5.1	108
23	A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5310-5319.	3.2	102
24	A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer. <i>Journal of Neuro-Oncology</i> , 2013, 113, 83-92.	1.4	97
25	Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases. <i>Annals of Oncology</i> , 2019, 30, 211-218.	0.6	96
26	Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases. <i>Lung Cancer</i> , 2018, 116, 62-66.	0.9	94
27	The RANO Leptomeningeal Metastasis Group proposal to assess response to treatment: lack of feasibility and clinical utility and a revised proposal. <i>Neuro-Oncology</i> , 2019, 21, 648-658.	0.6	90
28	How we treat patients with leptomeningeal metastases. <i>ESMO Open</i> , 2019, 4, e000507.	2.0	79
29	Chemotherapy-Related Neurotoxicity. <i>Current Neurology and Neuroscience Reports</i> , 2016, 16, 81.	2.0	77
30	Radionecrosis after stereotactic radiotherapy for brain metastases. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 903-914.	1.4	73
31	Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis. <i>European Journal of Cancer</i> , 2018, 95, 75-84.	1.3	72
32	SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. <i>Neuro-Oncology</i> , 2021, 23, 1835-1844.	0.6	64
33	Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer. <i>Neuro-Oncology</i> , 2020, 22, 524-538.	0.6	63
34	How we treat glioblastoma. <i>ESMO Open</i> , 2019, 4, e000520.	2.0	62
35	Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors. <i>Neuro-Oncology</i> , 2021, 23, 1100-1112.	0.6	59
36	Combined irradiation and targeted therapy or immune checkpoint blockade in brain metastases: toxicities and efficacy. <i>Annals of Oncology</i> , 2017, 28, 2962-2976.	0.6	57

#	ARTICLE	IF	CITATIONS
37	Detection and quantification of CSF malignant cells by the CellSearch [®] technology in patients with melanoma leptomeningeal metastasis. <i>Medical Oncology</i> , 2013, 30, 538.	1.2	55
38	Development of a new method for identification and quantification in cerebrospinal fluid of malignant cells from breast carcinoma leptomeningeal metastasis. <i>BMC Clinical Pathology</i> , 2012, 12, 21.	1.8	53
39	Cerebrospinal fluid concentrations of vemurafenib in patients treated for brain metastatic BRAF-V600 mutated melanoma. <i>Melanoma Research</i> , 2015, 25, 302-305.	0.6	53
40	Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma. <i>Neuro-Oncology</i> , 2016, 18, 401-407.	0.6	53
41	Diagnosis and treatment patterns for patients with leptomeningeal metastasis from solid tumors across Europe. <i>Journal of Neuro-Oncology</i> , 2017, 133, 419-427.	1.4	52
42	Waiting times before initiation of radiotherapy might not affect outcomes for patients with glioblastoma: a French retrospective analysis of patients treated in the era of concomitant temozolomide and radiotherapy. <i>Journal of Neuro-Oncology</i> , 2012, 109, 167-175.	1.4	51
43	REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours. <i>Annals of Oncology</i> , 2014, 25, 2351-2356.	0.6	51
44	CellSearch [®] technology applied to the detection and quantification of tumor cells in CSF of patients with lung cancer leptomeningeal metastasis. <i>Lung Cancer</i> , 2015, 90, 352-357.	0.9	42
45	Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2021, 32, 171-182.	0.6	42
46	Intracranial Cystic Lesions: A Review. <i>Current Neurology and Neuroscience Reports</i> , 2014, 14, 481.	2.0	40
47	Leptomeningeal metastases of solid cancer. <i>Current Opinion in Neurology</i> , 2016, 29, 797-805.	1.8	39
48	Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: A metanalysis with meta-regression. <i>Cancer Treatment Reviews</i> , 2020, 88, 102046.	3.4	39
49	Liquid biopsy in gliomas: A RANO review and proposals for clinical applications. <i>Neuro-Oncology</i> , 2022, 24, 855-871.	0.6	38
50	Evaluation of non-supervised MALDI mass spectrometry imaging combined with microproteomics for glioma grade III classification. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2017, 1865, 875-890.	1.1	36
51	SNCA locus duplication carriers: from genetics to Parkinson disease phenotypes. <i>Human Mutation</i> , 2011, 32, E2079-90.	1.1	34
52	Identification of single nucleotide polymorphisms of the PI3K-AKT-mTOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer. <i>European Journal of Cancer</i> , 2017, 87, 189-198.	1.3	34
53	Neurological complications of cancer immunotherapy. <i>Cancer Treatment Reviews</i> , 2021, 97, 102189.	3.4	34
54	Liquid biopsies for diagnosing and monitoring primary tumors of the central nervous system. <i>Cancer Letters</i> , 2020, 480, 24-28.	3.2	33

#	ARTICLE	IF	CITATIONS
55	A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormone therapy. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 569-580.	1.1	32
56	Working plan for the use of patient-reported outcome measures in adults with brain tumours: a Response Assessment in Neuro-Oncology (RANO) initiative. <i>Lancet Oncology</i> , The, 2018, 19, e173-e180.	5.1	32
57	Complications related to the use of an intraventricular access device for the treatment of leptomeningeal metastases from solid tumor: a single centre experience in 112 patients. <i>Journal of Neuro-Oncology</i> , 2015, 124, 317-323.	1.4	31
58	A phase II study of abemaciclib in patients (pts) with brain metastases (BM) secondary to HR+, HER2-metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 1017-1017.	0.8	31
59	Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism. <i>Nature Medicine</i> , 2022, 28, 752-765.	15.2	30
60	The future of high-grade glioma: Where we are and where are we going. , 2015, 6, 9.		29
61	Profound, durable and MGMT-independent sensitivity of glioblastoma cells to cyclin-dependent kinase inhibition. <i>International Journal of Cancer</i> , 2019, 145, 242-253.	2.3	27
62	Clinicopathological features of breast cancers predict the development of leptomeningeal metastases: a case-control study. <i>Journal of Neuro-Oncology</i> , 2011, 105, 309-315.	1.4	25
63	Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG). <i>Neuro-Oncology</i> , 2022, 24, 755-767.	0.6	25
64	Intradural Extramedullary Spinal Metastases of Non-neurogenic Origin. <i>Neurosurgery</i> , 2013, 73, 923-932.	0.6	24
65	Immunotherapy with CpG ODN in neoplastic meningitis: A phase I trial. <i>Cancer Science</i> , 2015, 106, 1212-1218.	1.7	24
66	Current Management of Adult Diffuse Infiltrative Low Grade Gliomas. <i>Current Neurology and Neuroscience Reports</i> , 2016, 16, 15.	2.0	23
67	Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1400-1407.	0.5	23
68	Anaplastic glioma: current treatment and management. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 601-620.	1.4	21
69	Systemic therapy for recurrent meningioma. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 889-901.	1.4	20
70	Neoplastic Meningitis Due to Lung, Breast, and Melanoma Metastases. <i>Cancer Control</i> , 2017, 24, 22-32.	0.7	20
71	Response assessment and outcome of combining immunotherapy and radiosurgery for brain metastasis from malignant melanoma. <i>ESMO Open</i> , 2020, 5, e000763.	2.0	20
72	Memory loss during lenalidomide treatment: a report on two cases. <i>BMC Pharmacology & Toxicology</i> , 2013, 14, 41.	1.0	19

#	ARTICLE	IF	CITATIONS
73	Determining medical decision-making capacity in brain tumor patients: why and how?. <i>Neuro-Oncology Practice</i> , 2020, 7, 599-612.	1.0	19
74	Patterns of response to crizotinib in recurrent glioblastoma according to ALK and MET molecular profile in two patients. <i>CNS Oncology</i> , 2015, 4, 381-386.	1.2	18
75	Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort. <i>Neuro-Oncology</i> , 2022, 24, 1726-1735.	0.6	18
76	Oligosarcomas, IDH-mutant are distinct and aggressive. <i>Acta Neuropathologica</i> , 2022, 143, 263-281.	3.9	18
77	CSF CA 15-3 in breast cancer-related leptomeningeal metastases. <i>Journal of Neuro-Oncology</i> , 2014, 117, 117-124.	1.4	17
78	Diagnostic value of 18F-fluorodesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site. <i>European Journal of Cancer</i> , 2018, 96, 64-72.	1.3	17
79	Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma. <i>Neurology</i> , 2019, 93, e1799-e1806.	1.5	17
80	The evolving role of neurosurgery for central nervous system metastases in the era of personalized cancer therapy. <i>European Journal of Cancer</i> , 2021, 156, 93-108.	1.3	16
81	Parvovirus H-1 induces cytopathic effects in breast carcinoma-derived cultures. <i>Breast Cancer Research and Treatment</i> , 2010, 121, 23-33.	1.1	15
82	Surgery followed by radiosurgery: A deliberate valuable strategy in the treatment of intracranial meningioma. <i>Clinical Neurology and Neurosurgery</i> , 2014, 124, 123-126.	0.6	14
83	Venous thrombosis in patients with high-grade glioma. <i>Current Opinion in Oncology</i> , 2015, 27, 516-521.	1.1	14
84	Angiotensin II receptor blockers, steroids and radiotherapy in glioblastoma: a randomised multicentre trial (ASTER trial). An ANOCEF study. <i>European Journal of Cancer</i> , 2019, 109, 129-136.	1.3	13
85	Trabectedin for recurrent WHO grade II or III meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG).. <i>Journal of Clinical Oncology</i> , 2019, 37, 2007-2007.	0.8	13
86	Sex-specific aspects of epidemiology, molecular genetics and outcome: primary brain tumours. <i>ESMO Open</i> , 2020, 5, e001034.	2.0	13
87	Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2022, 24, 1533-1545.	0.6	13
88	Cotard's syndrome with glioblastoma multiforme. <i>Palliative and Supportive Care</i> , 2012, 10, 135-139.	0.6	12
89	Temozolomide plus bevacizumab in elderly patients with newly diagnosed glioblastoma and poor performance status: An Anocef phase II trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2020-2020.	0.8	12
90	Associations of anticoagulant use with outcome in newly diagnosed glioblastoma. <i>European Journal of Cancer</i> , 2018, 101, 95-104.	1.3	11

#	ARTICLE	IF	CITATIONS
91	Venous thromboembolic events in patients with brain metastases: the PICOS score. <i>European Journal of Cancer</i> , 2020, 134, 75-85.	1.3	11
92	Different patterns of Mini Mental Status Examination responses in primary progressive aphasia and Alzheimer's disease. <i>European Journal of Neurology</i> , 2006, 13, 1124-1127.	1.7	10
93	Prolonged Response and Restoration of Functional Independence with Bevacizumab plus Vinorelbine as Third-Line Treatment for Breast Cancer-Related Leptomeningeal Metastases. <i>Case Reports in Oncology</i> , 2015, 8, 72-77.	0.3	10
94	Salvage intracerebrospinal fluid thiotepa in breast cancer-related leptomeningeal metastases. <i>Anti-Cancer Drugs</i> , 2013, 24, 1093-1097.	0.7	9
95	Imaging necrosis during treatment is associated with worse survival in EORTC 26101 study. <i>Neurology</i> , 2019, 92, e2754-e2763.	1.5	9
96	A New Landscape for Systemic Pharmacotherapy of Recurrent Glioblastoma?. <i>Cancers</i> , 2020, 12, 3775.	1.7	9
97	Systematic review on the use of patient-reported outcome measures in brain tumor studies: part of the Response Assessment in Neuro-Oncology Patient-Reported Outcome (RANO-PRO) initiative. <i>Neuro-Oncology Practice</i> , 2021, 8, 417-425.	1.0	9
98	Complications related to the placement of an intraventricular chemotherapy device. <i>Journal of Neuro-Oncology</i> , 2011, 104, 247-252.	1.4	8
99	Vascular complications in glioma patients. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2016, 134, 251-266.	1.0	8
100	Temozolomide and Bevacizumab Induction before Chemoradiotherapy in Patients with Bulky Glioblastoma and/or with Severe Neurological Impairment. <i>Journal of Cancer</i> , 2017, 8, 1417-1424.	1.2	8
101	Complementary and alternative medicine use in glioma patients in France. <i>Journal of Neuro-Oncology</i> , 2019, 145, 487-499.	1.4	8
102	Neurosurgical and radiosurgical decision making in brain metastasis patients in the area of targeted therapies?. <i>Chinese Clinical Oncology</i> , 2015, 4, 19.	0.4	8
103	Relevance of gamma knife radiosurgery alone for the treatment of non-small cell lung cancer brain metastases. <i>Clinical Neurology and Neurosurgery</i> , 2014, 125, 87-93.	0.6	7
104	Chemical meningitis related to intra-CSF liposomal cytarabine. <i>CNS Oncology</i> , 2017, 6, 261-267.	1.2	7
105	Underweight and weight loss are predictors of poor outcome in patients with brain metastasis. <i>Journal of Neuro-Oncology</i> , 2019, 145, 339-347.	1.4	7
106	Venous thromboembolic events in glioblastoma patients: An epidemiological study. <i>European Journal of Neurology</i> , 2022, 29, 2386-2397.	1.7	7
107	Occurrence of vismodegib-induced cramps (muscular spasms) in the treatment of basal cell carcinoma: A prospective study in 30 patients. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 1213-1216.e2.	0.6	6
108	Intra-CSF liposomal cytarabine plus systemic therapy as initial treatment of breast cancer leptomeningeal metastasis: A randomised, open-label trial. <i>Annals of Oncology</i> , 2018, 29, viii122.	0.6	6

#	ARTICLE	IF	CITATIONS
109	EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS2072-TPS2072.	0.8	6
110	Interferon γ sensitizes human glioblastoma cells to the cyclin-dependent kinase inhibitor, TG02. <i>Oncology Letters</i> , 2020, 19, 2649-2656.	0.8	6
111	Supportive care in neurooncology. <i>Revue Neurologique</i> , 2011, 167, 762-772.	0.6	5
112	Febrile neutropenia incidence and hematological toxicity with the FEC100-docetaxel regimen in the treatment of early-stage breast cancer. <i>Bulletin Du Cancer</i> , 2012, 99, E75-E80.	0.6	5
113	Treatment patterns, clinical outcomes and health care costs associated with her2-positive breast cancer with central nervous system metastases: a French multicentre observational study. <i>BMC Health Services Research</i> , 2013, 13, 456.	0.9	5
114	Radiation-associated grade 2 meningiomas: A nine patient-series and review of the literature. <i>Clinical Neurology and Neurosurgery</i> , 2015, 136, 10-14.	0.6	5
115	Evidence-based management of adult patients with diffuse glioma – Authors' reply. <i>Lancet Oncology</i> , 2017, 18, e430-e431.	5.1	5
116	Securing the circuit of intrathecally administered cancer drugs: example of a collective approach. <i>Journal of Oncology Pharmacy Practice</i> , 2011, 17, 252-259.	0.5	4
117	Rationale for the Use of Upfront Whole Brain Irradiation in Patients with Brain Metastases from Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2014, 15, 8138-8152.	1.8	4
118	Sensitivity of human meningioma cells to the cyclin-dependent kinase inhibitor, TG02. <i>Translational Oncology</i> , 2020, 13, 100852.	1.7	4
119	Antidepressant drug use in glioblastoma patients: an epidemiological view. <i>Neuro-Oncology Practice</i> , 2020, 7, 514-521.	1.0	4
120	Fitness-to-drive for glioblastoma patients. <i>Swiss Medical Weekly</i> , 2021, 151, w20501.	0.8	3
121	Ipilimumab combined with stereotactic radiosurgery in melanoma patients with brain metastases: A multicenter, open label, phase 2 trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9520-9520.	0.8	3
122	Molecular genetic, host-derived and clinical determinants of long-term survival in glioblastoma: First results from the ETERNITY study (EORTC 1419).. <i>Journal of Clinical Oncology</i> , 2019, 37, 2056-2056.	0.8	3
123	Prognosis of leptomeningeal metastases from melanoma: A case series of 28 patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, e13550-e13550.	0.8	3
124	Brain Metastases of Her2-Positive Breast Cancer: A Case of 34 Months' Remission with Lapatinib plus Capecitabine. <i>Case Reports in Oncology</i> , 2014, 7, 555-559.	0.3	2
125	ACTR-30. EORTC 1608: A PHASE 1B STUDY OF TG02, AN ORAL CYCLIN-DEPENDENT KINASE 9/5 INHIBITOR, IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA STRATIFIED BY MGMT PROMOTER METHYLATION STATUS. <i>Neuro-Oncology</i> , 2016, 18, vi8-vi8.	0.6	2
126	Leptomeningeal metastases from solid tumours. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 192-197.	0.3	2

#	ARTICLE	IF	CITATIONS
127	Ethanol Exposure During the Intravenous Administration of Chemotherapeutic Drugs: An Analysis of Clinical Practice and a Literature Review. JCO Oncology Practice, 2022, , OP2100430.	1.4	2
128	BM-18 * PROLONGED RESPONSE WITH BEVACIZUMAB + NAVELBINE AS THIRD LINE OF TREATMENT OF BREAST CANCER LEPTOMENINGEAL METASTASES: A CASE REPORT. Neuro-Oncology, 2014, 16, v36-v36.	0.6	1
129	Cerebral amyloid angiopathy revealed by rapidly progressing leptomeningeal lesions. Journal of Neurology, 2014, 261, 1432-1435.	1.8	1
130	BMET-18. DIAGNOSIS AND TREATMENT PATTERNS FOR PATIENTS WITH LEPTOMENINGEAL METASTASIS FROM SOLID TUMORS ACROSS EUROPE. Neuro-Oncology, 2016, 18, vi30-vi30.	0.6	1
131	Neoplastic Meningitis. , 2016, , 63-77.		1
132	Neuroradiology of Leptomeningeal Metastases. , 2016, , 705-721.		1
133	Farewell to monomodality treatment in patients with WHO lower grade glioma?. European Journal of Cancer, 2018, 88, 109-114.	1.3	1
134	Associations of anticoagulant use with outcome in newly diagnosed glioblastoma.. Journal of Clinical Oncology, 2018, 36, e14070-e14070.	0.8	1
135	Leptomeningeal Disease. Hematology/Oncology Clinics of North America, 2021, 36, 189-215.	0.9	1
136	NIMG-01. INTEROBSERVER VARIABILITY OF THE REVISED IMAGING SCORECARD FOR LEPTOMENINGEAL METASTASIS: A JOINT EORTC BRAIN TUMOR GROUP AND RANO EFFORT. Neuro-Oncology, 2021, 23, vi126-vi127.	0.6	1
137	Associations of levetiracetam use with the safety and tolerability profile of chemoradiotherapy for patients with newly diagnosed glioblastoma. Neuro-Oncology Advances, 2022, 4, .	0.4	1
138	Essentials for clinicians: head and neck tumours and neuro-oncology. ESMO Open, 2016, 1, e000156.	2.0	0
139	Neurological Complications of Breast Cancer and Its Treatment. , 2018, , 435-469.		0
140	Leptomeningeal Metastasis as Complication of Systemic Cancers. , 2018, , 81-111.		0
141	P01.041 Secondary prophylaxis with romiplostim for temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma. Neuro-Oncology, 2018, 20, iii238-iii238.	0.6	0
142	P01.034 Prospective evaluation of alternative therapies in glioma patients in France. Neuro-Oncology, 2018, 20, iii236-iii236.	0.6	0
143	P04.11 Profound sensitivity of glioblastoma cells to apoptosis induction by TG02, a novel oral multi-cyclin-dependent kinase inhibitor. Neuro-Oncology, 2018, 20, iii280-iii280.	0.6	0
144	OS8.6 Sensitivity of human meningioma cells to the cyclin-dependent kinase inhibitor, TG02. Neuro-Oncology, 2019, 21, iii17-iii17.	0.6	0

#	ARTICLE	IF	CITATIONS
145	EPID-10. VENOUS THROMBOEMBOLIC EVENTS IN GLIOBLASTOMA PATIENTS: AN EPIDEMIOLOGICAL VIEW. <i>Neuro-Oncology</i> , 2019, 21, vi76-vi76.	0.6	0
146	DDIS-04. INTERFERON- γ SENSITIZES HUMAN GLIOBLASTOMA CELLS TO THE CYCLIN-DEPENDENT KINASE INHIBITOR, TG02. <i>Neuro-Oncology</i> , 2019, 21, vi65-vi66.	0.6	0
147	DEPOSEINâ€”how meaningful was the benefit from intrathecal chemotherapy?. <i>Neuro-Oncology</i> , 2020, 22, 1710-1711.	0.6	0
148	SURG-10. The evolving role of neurosurgery for central nervous system metastases in the era of personalized medicine. <i>Neuro-Oncology Advances</i> , 2021, 3, iii25-iii25.	0.4	0
149	Identification of single nucleotide polymorphism of PI3k-AKT-TOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2007-2007.	0.8	0
150	The value of ¹⁸ F-fluorodesoxyglucose positron emission tomography (FDG-PET/CT) in the detection of the primary lesion and for staging in brain metastasis (BM) patients with cancer of unknown primary site (CUPS).. <i>Journal of Clinical Oncology</i> , 2017, 35, 2076-2076.	0.8	0
151	Secondary prophylaxis with romiplostim for temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2042-2042.	0.8	0
152	Validation and revision of the RANO Leptomeningeal Metastasis Group scorecard for response assessment.. <i>Journal of Clinical Oncology</i> , 2019, 37, e13546-e13546.	0.8	0
153	Treatment of Leptomeningeal Metastases. , 2020, , 301-311.		0
154	Clinical, Imaging, and CSF Cytological Presentation of Leptomeningeal Metastases from Solid Non-CNS Primary Tumors. , 2020, , 173-179.		0
155	Venous thromboembolic events in glioblastoma patients: Common complication but not a major reason for death.. <i>Journal of Clinical Oncology</i> , 2020, 38, e14530-e14530.	0.8	0
156	Response assessment and outcome of combining immunotherapy and radiosurgery for brain metastasis from malignant melanoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2532-2532.	0.8	0
157	Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2055-2055.	0.8	0
158	Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2026-2026.	0.8	0